Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs

Journal of Veterinary Internal Medicine

Volumn 22, Issue 1, 2008, Pages 53-59

  Lascelles, B D X ^a   Gaynor, J S ^b   Smith, E S ^a   Roe, S C ^a   Marcellin Little, D J ^a   Davidson, G ^a   Boland, E ^a   Carr, J ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Animal Anesthesia and Pain Management Center   (United States)

Author keywords

Dog; Nonsteroidal anti inflammatory; Owner; Pain; Subjective assessment

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

EID: 40549119855     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2007.0014.x     Document Type: Article

References (60)

1. 1 Holtsinger RH, Parker RB, Beale BS, et al. The therapeutic efficacy of carprofen (Rimadyl‐V) in 209 clinical cases of canine degenerative joint disease. Vet Comp Orthopedics Traumatol 1992 ; 5: 140–144.
2. 2 Hazewinkel HA, Van Den Brom WE, Theijse LF, et al. Reduced dosage of ketoprofen for the short‐term and long‐term treatment of joint pain in dogs. Vet Rec 2003 ; 152: 11–14.
3. 3 Budsberg SC, Johnston SA, Schwarz PD, et al. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 1999 ; 214: 206–210.
4. 4 Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti‐inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995 ; 206: 807–811.
5. 5 Freedman GM. Chronic pain. Clinical management of common causes of geriatric pain. Geriatrics 2002 ; 57: 36–41 ; quiz 42.
6. 6 Wieland HA, Michaelis M, Kirschbaum BJ, et al. Osteoarthritis—an untreatable disease? Nat Rev Drug Discov 2005 ; 4: 331–344.
7. 7 Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet 2005 ; 365: 965–973.
8. 8 Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. Pain 2004 ; 111: 286–296.
9. 9 Emkey R, Rosenthal N, Wu SC, et al. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add‐on therapy for osteoarthritis pain in subjects receiving a COX‐2 nonsteroidal antiinflammatory drug: A multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004 ; 31: 150–156.
10. 10 Altman RD, Hochberg M, Moskowitz RW, et al. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000 ; 43: 1905–1915.
11. 11 Lascelles BD, Main DC. Surgical trauma and chronically painful conditions—within our comfort level but beyond theirs? J Am Vet Med Assoc 2002 ; 221: 215–222.
12. 12 Todd C. Meeting the therapeutic challenge of the patient with osteoarthritis. J Am Pharm Assoc (Wash) 2002 ; 42: 74–82.
13. 13 Wilder‐Smith CH, Hill L, Spargo K, et al. Treatment of severe pain from osteoarthritis with slow‐release tramadol or dihydrocodeine in combination with NSAID's: A randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001 ; 91: 23–31.
14. 14 Galer BS, Sheldon E, Patel N, et al. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 2004 ; 20: 1455–1458.
15. 15 Cepeda MS, Camargo F, Zea C, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006 ; 3: CD005522.
16. 16 Kosek E, Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur J Pain 2000 ; 4: 229–238.
17. 17 Ordeberg G. Characterization of joint pain in human OA. Novartis Found Symp 2004 ; 260: 105–115 ; discussion 115–121, 277–109.
18. 18 Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000 ; 288: 1765–1769.
19. 19 Pace MC, Mazzariello L, Passavanti MB, et al. Neurobiology of pain. J Cell Physiol 2006 ; 209: 8–12.
20. 20 Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1‐adamantanamine (amantadine). Science 1964 ; 144: 862–863.
21. 21 Schwab RS, Poskanzer DC, England AC Jr, et al. Amantadine in Parkinson's disease. Review of more than two years' experience. JAMA 1972 ; 222: 792–795.
22. 22 Schwab RS, England AC Jr, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969 ; 208: 1168–1170.
23. 23 Blanpied TA, Boeckman FA, Aizenman E, et al. Trapping channel block of NMDA‐activated responses by amantadine and memantine. J Neurophysiol 1997 ; 77: 309–323.
24. 24 Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005 ; 25: 3312–3322.
25. 25 Eisenberg E, Pud D. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine? Pain 1998 ; 74: 337–339.
26. 26 Pud D, Eisenberg E, Spitzer A, et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: A double blind, randomized, placebo controlled trial. Pain 1998 ; 75: 349–354.
27. 27 Taira T. Comments on Eisenberg and Pud, Pain 74 (1998) 337–339. Pain 1998 ; 78: 221–222.
28. 28 Kleinbohl D, Gortelmeyer R, Bender HJ, et al. Amantadine sulfate reduces experimental sensitization and pain in chronic back pain patients. Anesth Analg 2006 ; 102: 840–847.
29. 29 Bleidner WE, Harmon JB, Hewes WE, et al. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 1965 ; 150: 484–490.
30. 30 Gingerich DA, Strobel JD. Use of client‐specific outcome measures to assess treatment effects in geriatric, arthritic dogs: Controlled clinical evaluation of a nutraceutical. Vet Ther 2003 ; 4: 56–66.
31. 31 Lascelles BD, Hansen BD, Roe S, et al. Evaluation of client‐specific outcome measures and activity monitoring to measure pain relief in cats with osteoarthritis. J Vet Intern Med 2007 ; 21: 410–416.
32. 32 Innes JF, Barr AR. Clinical natural history of the postsurgical cruciate deficient canine stifle joint: Year 1. J Small Anim Pract 1998 ; 39: 325–332.
33. 33 Clements DN, Carter SD, Innes JF, et al. Genetic basis of secondary osteoarthritis in dogs with joint dysplasia. Am J Vet Res 2006 ; 67: 909–918.
34. 34 Hays L, Zhang Z, Mateescu RG, et al. Quantitative genetics of secondary hip joint osteoarthritis in a Labrador Retriever‐Greyhound pedigree. Am J Vet Res 2007 ; 68: 35–41.
35. 35 Smith GK, Paster ER, Powers MY, et al. Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs. J Am Vet Med Assoc 2006 ; 229: 690–693.
36. 36 Manek NJ, Lane NE. Osteoarthritis: Current concepts in diagnosis and management. Am Fam Physician 2000 ; 61: 1795–1804.
37. 37 Schnitzer TJ. Non‐NSAID pharmacologic treatment options for the management of chronic pain. Am J Med 1998 ; 105: 45S–52S.
38. 38 Mullican WS, Lacy JR. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: A comparative trial. Clin Ther 2001 ; 23: 1429–1445.
39. 39 Woolf CJ. Evidence for a central component of post‐injury pain hypersensitivity. Nature 1983 ; 306: 686–688.
40. 40 Urban L, Thompson SWN, Dray A. Modulation of spinal excitability: Co-operation between neurokinin and excitatory amino acid neurotransmitters. Trends in Neurosciences 1994 ; 17: 432–438.
41. 41 Graven‐Nielsen T, Arendt‐Nielsen L. Peripheral and central sensitization in musculoskeletal pain disorders: An experimental approach. Curr Rheumatol Rep 2002 ; 4: 313–321.
42. 42 Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001 ; 413: 203–210.
43. 43 Li W, Neugebauer V. Block of NMDA and non‐NMDA receptor activation results in reduced background and evoked activity of central amygdala neurons in a model of arthritic pain. Pain 2004 ; 110: 112–122.
44. 44 Sharif Naeini R, Cahill CM, Ribeiro‐da‐Silva A, et al. Remodelling of spinal nociceptive mechanisms in an animal model of monoarthritis. Eur J Neurosci 2005 ; 22: 2005–2015.
45. 45 Lascelles BD, Robertson SA. Antinociceptive effects of hydromorphone, butorphanol, or the combination in cats. J Vet Intern Med 2004 ; 18: 190–195.
46. 46 Lascelles BD, Robertson SA. Use of thermal threshold response to evaluate the antinociceptive effects of butorphanol in cats. Am J Vet Res 2004 ; 65: 1085–1089.
47. 47 Robertson SA, Lascelles BD, Taylor PM, et al. PK‐PD modeling of buprenorphine in cats: Intravenous and oral transmucosal administration. J Vet Pharmacol Ther 2005 ; 28: 453–460.
48. 48 Lascelles BD, Cripps PJ, Jones A, et al. Post‐operative central hypersensitivity and pain: The pre-emptive value of pethidine for ovariohysterectomy. Pain 1997 ; 73: 461–471.
49. 49 KuKanich B, Lascelles BD, Papich MG. Use of a von Frey device for evaluation of pharmacokinetics and pharmacodynamics of morphine after intravenous administration as an infusion or multiple doses in dogs. Am J Vet Res 2005 ; 66: 1968–1974.
50. 50 KuKanich B, Lascelles BD, Papich MG. Assessment of a von Frey device for evaluation of the antinociceptive effects of morphine and its application in pharmacodynamic modeling of morphine in dogs. Am J Vet Res 2005 ; 66: 1616–1622.
51. 51 Lascelles BD, Hansen BD, Thomson A, et al. Evaluation of a digitally integrated accelerometer‐based activity monitor for the measurement of activity in cats. Vet Anaest Analg 2007, in press.
52. 52 Lascelles BDX, Hansen BD, Roe SC, et al. Evaluation of client‐specific outcome measures and activity monitoring to measure pain relief in cats with osteoarthritis. J Vet Intern Med 2007 ; 21: 410–416.
53. 53 Hielm‐Bjorkman AK, Kuusela E, Liman A, et al. Evaluation of methods for assessment of pain associated with chronic osteoarthritis in dogs. J Am Vet Med Assoc 2003 ; 222: 1552–1558.
54. 54 Fisher K, Hardie RJ. Goal attainment scaling in evaluating a multidisciplinary pain management programme. Clin Rehabil 2002 ; 16: 871–877.
55. 55 Hurn J, Kneebone I, Cropley M. Goal setting as an outcome measure: A systematic review. Clin Rehabil 2006 ; 20: 756–772.
56. 56 Wiseman ML, Nolan AM, Reid J, et al. Preliminary study on owner‐reported behaviour changes associated with chronic pain in dogs. Vet Rec 2001 ; 149: 423–424.
57. 57 Wiseman‐Orr ML, Nolan AM, Reid J, et al. Development of a questionnaire to measure the effects of chronic pain on health‐related quality of life in dogs. Am J Vet Res 2004 ; 65: 1077–1084.
58. 58 Vernier VG, Harmon JB, Stump JM, et al. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol 1969 ; 15: 642–665.
59. 59 Kolbe F, Sitar DS, Papaioannou A, et al. An amantadine hydrochloride dosing program adjusted for renal function during an influenza outbreak in elderly institutionalized patients. Can J Clin Pharmacol 2003 ; 10: 119–122.
60. 60 Miller KS, Miller JM. Toxic effects of amantadine in patients with renal failure. Chest 1994 ; 105: 1630.